HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Final Quarter Of P&G CEO Taylor’s Tenure Could Become Stormy With Headwinds From Rising Costs

Executive Summary

P&G’s health care sector’s net sales grew 18% in its latest quarter. Continued growth across its sectors is critical in the face of expected $1.8bn in headwinds from commodity and freight costs in its FY2022.

You may also be interested in...



P&G Among US Firms Asked To Explain How, Why Supply Chain Problems Cause Consumer Hardships

Procter & Gamble and Amazon are among nine companies FTC ordered to provide detailed information to help the agency identify causes behind ongoing supply chain disruptions. Chairwoman Khan says the information should “shed light on market conditions and business practices that may have worsened these disruptions.”

P&G Increasing US Product Prices More Broadly With Commodity Headwinds Still Strong

P&G raises prices on 9 of its 10 US product categories, rolling out increases in grooming, skin care and oral care products now. High commodity costs prompted it to increase its outlook for headwinds of $2.1bn for its FY2022.

US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan

July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS151608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel